Here's Why the Novavax Vaccine May Have to Wait for FDA Authorization

Novavax's (NASDAQ:NVAX) investigational coronavirus vaccine is on its way to the big finish line: regulatory authorization. The company recently reported positive phase 3 data. And now, regulatory agencies in the U.S., Europe, the U.K., and Canada are conducting rolling reviews. If Novavax follows in the footsteps of more advanced rivals Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA), we could imagine a vaccine on the market in a matter of weeks.